Biopharma · FDA Approvals · Stock
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to bl…
Assets on file: vensobafusp alfa
Dated catalysts for JSPR, including recently decided ones.
Every first-hand event for JSPR, newest first.
vensobafusp alfa · NCT05504187 registry update
status: NOT_YET_RECRUITING → WITHDRAWN; enrollment: 24 → 0; why_stopped: → Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns
vensobafusp alfa · NCT05476887 registry update
status: ACTIVE_NOT_RECRUITING → UNKNOWN
Jasper Therapeutics Completes IgAN Cohort Enrollment in Phase 2 Basket Study of Vensobafusp Alfa (KP104)
Jasper completed enrollment of 18 patients in Stage 1 of its Phase 2 renal basket study evaluating vensobafusp alfa in IgA nephropathy across three dosing cohorts. Initial interim data from the IgAN cohort is now expected by year-end 2026. The company also announced an expansion cohort in FSGS patients with first dosing anticipated in Q1 2027.
Jasper Therapeutics completes enrollment in Phase 2 renal basket study of vensobafusp alfa in IgAN
This earnings release recaps completion of enrollment in the first cohort of the Phase 2 renal basket study of vensobafusp alfa (KP104) in IgA nephropathy patients. The company plans to report interim data in Q4 2026 and updated data in Q1 2027. It also notes commencement of enrollment in the IC-MPGN cohort and opening of an FSGS expansion cohort with first dosing expected in Q1 2027.
Companies in the same sector closest to JSPR in market value.